Shares of Evoke Pharma Inc. (NASDAQ:EVOK) were up 3.7% during mid-day trading on Thursday . The company traded as high as $2.27 and last traded at $2.24, with a volume of 297,268 shares. The stock had previously closed at $2.16.

EVOK has been the subject of several research reports. FBR & Co lifted their target price on shares of Evoke Pharma to $9.00 and gave the company an “outperform” rating in a report on Tuesday, July 19th. Rodman & Renshaw downgraded shares of Evoke Pharma from a “buy” rating to a “neutral” rating and set a $2.00 target price for the company. in a report on Monday, July 18th. Brean Capital downgraded shares of Evoke Pharma from a “buy” rating to a “hold” rating in a report on Monday, July 18th. Feltl & Co. downgraded shares of Evoke Pharma from a “strong-buy” rating to a “sell” rating in a report on Monday, July 18th. Finally, Northland Securities downgraded shares of Evoke Pharma from an “outperform” rating to a “market perform” rating in a report on Monday, July 18th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the stock. Evoke Pharma currently has an average rating of “Hold” and an average target price of $13.34.

The company has a 50-day moving average of $5.01 and a 200-day moving average of $4.71. The firm’s market capitalization is $16.15 million.

Evoke Pharma (NASDAQ:EVOK) last released its earnings results on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by $0.04. Analysts forecast that Evoke Pharma Inc. will post ($1.43) EPS for the current year.

In related news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of Evoke Pharma stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $4.70, for a total transaction of $1,617,364.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.